370 related articles for article (PubMed ID: 17440739)
1. Sulfasalazine-induced pericarditis in a patient with ulcerative colitis without recurrence when switching to mesalazine.
Perrot S; Aslangul E; Szwebel T; Gadhoum H; Romnicianu S; Le Jeunne C
Int J Colorectal Dis; 2007 Sep; 22(9):1119-21. PubMed ID: 17440739
[TBL] [Abstract][Full Text] [Related]
2. Pleuropericarditis in a patient with ulcerative colitis in longstanding 5-aminosalicylic acid therapy.
Iaquinto G; Sorrentini I; Petillo FE; Berardesca G
Ital J Gastroenterol; 1994 Apr; 26(3):145-7. PubMed ID: 8061342
[TBL] [Abstract][Full Text] [Related]
3. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
Nakajima H; Munakata A; Yoshida Y
J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
[TBL] [Abstract][Full Text] [Related]
4. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine.
Habal FM; Greenberg GR
Am J Gastroenterol; 1988 Jan; 83(1):15-9. PubMed ID: 2892391
[TBL] [Abstract][Full Text] [Related]
5. [Pericarditis during inflammatory bowel diseases. Extra-intestinal or iatrogenic complication?].
Heresbach D; Rabot A; Génetet N; Marteau P; Stéphan C; Bretagne JF; Gosselin M
Gastroenterol Clin Biol; 1994; 18(8-9):782-5. PubMed ID: 7875451
[TBL] [Abstract][Full Text] [Related]
6. [Ulcerative colitis and pericarditis. The role of mesalazine hypersensitivity].
Loizeau E
Rev Med Suisse Romande; 1995 Nov; 115(11):935-8. PubMed ID: 8525252
[No Abstract] [Full Text] [Related]
7. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
Schroeder KW
Scand J Gastroenterol Suppl; 2002; (236):42-7. PubMed ID: 12408503
[TBL] [Abstract][Full Text] [Related]
8. Drug induced otalgia due to mesalazine and sulphasalazine.
Wareing M; Mitchell D
J Laryngol Otol; 1996 May; 110(5):466-7. PubMed ID: 8762319
[TBL] [Abstract][Full Text] [Related]
9. 5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis.
Walker AM; Szneke P; Bianchi LA; Field LG; Sutherland LR; Dreyer NA
Am J Gastroenterol; 1997 May; 92(5):816-20. PubMed ID: 9149192
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.
Rutgeerts P
Aliment Pharmacol Ther; 1989 Apr; 3(2):183-91. PubMed ID: 2577483
[TBL] [Abstract][Full Text] [Related]
11. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
Gut; 1988 May; 29(5):669-74. PubMed ID: 2899536
[TBL] [Abstract][Full Text] [Related]
12. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
Rachmilewitz D
BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
[TBL] [Abstract][Full Text] [Related]
13. Ulcerative colitis: responding to the challenges.
Achkar JP
Cleve Clin J Med; 2007 Sep; 74(9):657-60. PubMed ID: 17879519
[TBL] [Abstract][Full Text] [Related]
14. [Salazosulfapyridine or 5-aminosalicylic acid].
van Hees PA
Ned Tijdschr Geneeskd; 1987 May; 131(22):931-4. PubMed ID: 2885762
[No Abstract] [Full Text] [Related]
15. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis.
Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
Gastroenterology; 1988 Jun; 94(6):1383-9. PubMed ID: 2896139
[TBL] [Abstract][Full Text] [Related]
16. Mesalamine in ulcerative colitis.
Fitzgerald JM; Marsh TD
DICP; 1991 Feb; 25(2):140-5. PubMed ID: 1676200
[TBL] [Abstract][Full Text] [Related]
17. 5-ASA induced recurrent myopericarditis and cardiac tamponade in a patient with ulcerative colitis.
Sonu I; Wong R; Rothenberg ME
Dig Dis Sci; 2013 Aug; 58(8):2148-50. PubMed ID: 23361575
[No Abstract] [Full Text] [Related]
18. [Rescue therapy with sulfasalazine prior to immunosuppressive or biological agents in ulcerative colitis poorly controlled with mesalazine].
Martínez González J; Busto Bea V; Mesonero Gismero F; Parejo Carbonell S; Garrido E; López San Román A
Gastroenterol Hepatol; 2013 Jan; 36(1):7-10. PubMed ID: 23195755
[TBL] [Abstract][Full Text] [Related]
19. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group.
Rijk MC; van Lier HJ; van Tongeren JH
Am J Gastroenterol; 1992 Apr; 87(4):438-42. PubMed ID: 1348159
[TBL] [Abstract][Full Text] [Related]
20. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis.
Sutherland LR; May GR; Shaffer EA
Ann Intern Med; 1993 Apr; 118(7):540-9. PubMed ID: 8095128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
